Latest News

Latest News

News from the World Hepatitis Alliance

Catch up on the FIND webinar on hepatitis C diagnostics

28 Nov 2019 Chris Wingrove

On Wednesday the 27th November we were joined by FIND for a webinar on the diagnositcs landscape of hepatitis C testing. If you missed the webinar...

hepVoice November is Out Now

20 Nov 2019 Lucy Ferrier

The latest issue of hepVoice is out now. In this issue: + Global hepatology societies call for better hepatitis C testing and access to treatment; +...

hepinion: decentralisation and task shifting will accelerate the elimination of viral hepatitis

19 Nov 2019 Lucy Ferrier

We will not achieve the elimination of hepatitis C if we do not reach those most at-risk and most affected. The decentralisation of services will help us test, treat and cure marginalised and at-risk communities, wherever they are....

Nominate your candidate to stand for election as a WHA Regional Board Member.

7 Nov 2019 Isabel Bull

Nominations are open for candidates to stand for election as the World Hepatitis Alliance (WHA) Regional Board Members for the African (AFRO),...

hepVoice October is out now

21 Oct 2019 Lucy Ferrier

The latest issue of hepVoice is out now. In this issue: World Hepatitis Alliance welcomes 10 new members; Universal Health Coverage: what it means...

hepinion: global funders must join the fight for hepatitis elimination

16 Oct 2019 Lucy Ferrier

by Dr Philip Bruggman Earlier this month, the Global Fund met for its sixth replenishment meeting in Lyon, France, where it achieved its ambitious...

EVENT: Universal Health Coverage & HIV – The Potential Impact of Collaborative Innovations with Viral Hepatitis Elimination

1 Oct 2019 Lucy Ferrier

The World Hepatitis Alliance, in collaboration with ICE-HBV and partners, are organising a session at the Global Fund’s replenishment conference in Lyon on 8 October....

The World Hepatitis Alliance and UNITE partner to combat viral hepatitis

26 Sep 2019 Lucy Ferrier

LONDON, UNITED KINGDOM (September 26, 2019) The World Hepatitis Alliance (WHA) and UNITE, the global parliamentarians network to end HIV/AIDS, viral...

Universal Health Coverage: what it means for viral hepatitis

25 Sep 2019 Lucy Ferrier

- written by Cary James, World Hepatitis Alliance CEO On Monday 23rd September I attended the United Nations (UN) High Level Meeting on Universal...

WHA and UNITE host side meeting at the United Nations High-Level Meeting on UHC

19 Sep 2019 Chris Wingrove

Securing political leadership and innovative funding to achieve Universal Health Coverage. Where: UNAIDS New York office, 801 2nd Avenue/43rd St....

United Against Hepatitis- A Network for Hepatitis Free Society

12 Sep 2019 Isabel Bull

In 2016, 194 governments including that of India committed to eliminating viral hepatitis as a public health threat by 2030. In doing so, India has committed to diagnosing 30 per cent of people living with viral hepatitis by 2020 and 90 per cent of people by 2030....

World Hepatitis Alliance and IAPAC Announce Fast-Track Cities Partnership

9 Sep 2019 Lucy Ferrier

The World Hepatitis Alliance (WHA) and the International Association of Providers of AIDS Care (IAPAC) announced a new partnership today on the first day of the Fast-Track Cities 2019 conference in London....

hepinion: Exploring a pioneering catalytic funding mechanism for elimination in Uzbekistan

3 Sep 2019 Tash Priya

In Uzbekistan around 5,300 people die each year from liver disease and cancer related to hepatitis B or C. The tragedy is that almost all of these deaths are preventable. Uzbekistan, like many other low- to middle-income countries, faces a huge economic and social burden because of viral hepatitis. With no global funder present to help them to tackle the disease, new innovative models of financing need to be explored to make hepatitis elimination a reality....

PRIME® launch Practical Toolkit for Building a Successful Partnership with High-Risk Hepatitis C Patients.

29 Aug 2019 Lucy Ferrier

Leading healthcare education and research company PRIME® has launched a practical toolkit aimed at aligning patients and providers in the prevention and treatment of hepatitis C....

World Hepatitis Day special: hepVoice August is Out Now

27 Aug 2019 Lucy Ferrier

The August 2019 edition of hepVoice, the monthly e-magazine from the World Hepatitis Alliance....

hepinion: We must invest in viral hepatitis

30 Jul 2019 Chris Wingrove

Earlier this year JHEP released an article entitled ‘Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017’. Encouragingly, the article concludes that countries are making progress with respect to national hepatitis planning. However, there remains a major issue: financing....

hepVoice July is Out Now

25 Jul 2019 Lucy Ferrier

The July 2019 edition of hepVoice, the monthly e-magazine from the World Hepatitis Alliance...

Presidents message ahead of World Hepatitis Day

25 Jul 2019 Chris Wingrove

World Hepatitis Day is the one day when the world unites to celebrate the progress made towards the elimination of viral hepatitis. Progress that has...

hepinion: stigma and discrimination affects everyone

10 Jul 2019 Lucy Ferrier

On April 21, 2019, the shocking news came out that Pakistani cricketer Shadab Khan had been ruled out of the series against England prior to the Cricket World Cup 2019 after being diagnosed with hepatitis C. Shadab is a key player of Pakistan, the only specialist spinner in the 15 player squad. It’s really unfortunate for someone just diagnosed with hepatitis C to be withdrawn from their duties, and entirely unnecessary. If a renowned player like Shadab Khan became a victim of discrimination than what about common people?...

hepVoice June is Out Now

26 Jun 2019 Lucy Ferrier

The June 2019 edition of hepVoice, the monthly e-magazine from the World Hepatitis Alliance...

Pages

News from infohep

Immunotherapy combination improves liver cancer survival

27 Nov 2019 Liz Highleyman
A combination of nivolumab (Opdivo) and ipilimumab (Yervoy), two different types of checkpoint inhibitor immunotherapy, led to higher response rates...

New NASH therapies show promise in mid-stage studies

26 Nov 2019 Liz Highleyman
Phase II study results presented at the AASLD Liver Meeting this month in Boston show that a number of experimental therapies improve markers of...

People with fatty liver disease struggle to lose weight

25 Nov 2019 Liz Highleyman
Losing weight may be especially difficult for people with fatty liver disease due to differences in their metabolism. But nonetheless, some can...

Sustained response to HCV antivirals boosts liver cancer survival

19 Nov 2019 Liz Highleyman
People with liver cancer who achieved a sustained virological response (SVR) to direct-acting antiviral (DAA) therapy for hepatitis C saw a reduction...

Hepatitis B antiviral drugs reduce liver cancer risk

19 Nov 2019 Liz Highleyman
Treating hepatitis B virus (HBV) with nucleoside/nucleotide antiviral drugs was associated with a lower risk of developing hepatocellular carcinoma (...

Hepatitis C incidence is low among Canadian men on PrEP

18 Nov 2019 Liz Highleyman
New cases of hepatitis C virus (HCV) infection among Canadian gay and bisexual men taking pre-exposure prophylaxis (PrEP) were uncommon compared...

Pre- and post-transplant antiviral treatment prevents hepatitis C transmission in all organ recipients, Canadian study finds

14 Nov 2019 Keith Alcorn
Adding a cholesterol-lowering drug to direct-acting antivirals (DAAs) prevented hepatitis C infection in all recipients of organ transplants from...

Coalition of liver associations calls for simplifying hepatitis C care

13 Nov 2019 Liz Highleyman
Leaders of liver disease associations from Europe, the United States, Latin America and Asia issued a global call to action at the AASLD Liver...

Therapeutic hepatitis B vaccine may lead to functional cure

13 Nov 2019 Liz Highleyman
An experimental therapeutic vaccine called NASVAC, which targets two different hepatitis B virus (HBV) antigens, led to a reduction in hepatitis B...

Emricasan and selonsertib fail to improve fibrosis in people with NASH

12 Nov 2019 Liz Highleyman
A pair of experimental therapies for non-alcoholic steatohepatitis (NASH) failed to offer notable improvements in controlled clinical trials, despite...